Transhuman Capital is a venture capital firm that invests in pharmaceuticals, medical devices, and other technologies. Their aim is to create a society in which everyone can live a long, healthy, daring, and meaningful life.

Transhuman Capital

QVT Financial LP is a privately owned hedge fund sponsor. The firm provides its services to pooled investment vehicles. It invests in public equity and debt across the globe. The firm also invests in alternative investment markets across the globe. It invests in structured finance, private placements, high yield, and distressed debt to create its portfolios. The firm employs convertible arbitrage, investment grade, and capital structure arbitrage techniques along with closed-end fund arbitrage and various relative value-driven equity strategies such as risk arbitrage, fundamental relative value, statistical trades, and other special situation techniques to its investments. QVT Financial is based in New York, New York with an additional office in London, United Kingdom.

QVT Financial

Foresite Capital is a healthcare and life sciences investment firm. They take a data-driven approach to invest in startups that employ biology and big data to improve healthcare, such as 10x Genomics, Relay Therapeutics, Element Biosciences, and Inscripta.

Foresite Capital

Dexcel Pharma is Israel’s largest private pharmaceutical company. Founded in 1968, they develop, manufacture and market value-added branded and generic pharmaceuticals. With a diverse product portfolio that spans more than 55 branded and generic products in over 140 dosage forms, our products are sold in the US, the UK, and Germany, via subsidiaries and through a trusted network of partners in more than 30 countries worldwide.

Dexcel Pharma

The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Through partnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.

JDRF T1D Fund

Amplo is a global venture capital firm helping build companies that matter. It specializes in the fields of financial services, venture capital and financial exchanges. Amplo was founded in 2017 and headquartered in Spring, Texas.

Amplo

Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.

Sahsen Ventures

BlueBird Ventures is a venture capital fund that is managed by Sutter Hill Ventures.

Bluebird Ventures

Narya Capital is an early-stage venture capital firm that focuses on using technology and science to address critical problems facing America. The firm backs founders and companies taking bold steps forward in areas such as healthcare, agriculture, defense, and financial services.

Narya Capital

Patient Square Capital focuses on a healthcare investment firm that partners with best-in-class management teams whose products, services, and technologies improve health. They use extensive industry expertise, a large network of relationships, and a partnership approach to help organizations develop and succeed.

Patient Square Capital

CAM Capital manages private family investments. The firm’s goal is to achieve long-term compounded growth of its portfolio using a diversified, opportunistic investment strategy. In pursuit of this goal, CAM Capital engages in both trading activities and fundamentally driven investments. Our investments span all parts of the corporate capital structure in both the private and public markets.  ###Caxton Alternative Management announced that it is changing its name to CAM Capital.###

CAM Capital

Alumni Ventures Group provides high-quality, diversified venture portfolios to individual investors who previously haven't had access to VC. It helps accredited alums from top entrepreneurial schools invest together in the ventures of fellow alums. The firm backs companies with an alumni connection and an institutional lead investor with expertise in the space. AVG also offers focused funds that allow any accredited investor access to a venture portfolio, diversified by type, sector, stage, and geography. Beth Obermiller, Michael Madden, and Mike Collins co-founded the firm in Manchester, New Hampshire in 2013.

Alumni Ventures

Woodline Partners is a private equity firm that focuses on the healthcare and technology sectors. The firm was founded in 2018 and is based in San Francisco, California, United States.

Woodline Partners

Hongkou

Lightswitch Capital is a venture capital firm.

Lightswitch Capital

Kriya Therapeutics

Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy. They have built a fully integrated engine that consolidates the critical infrastructure and technology needed to engineer, manufacture, characterize, and develop new gene therapies

California-based Kriya Therapeutics develops gene therapies for three focus areas: ophthalmology, neurology, and metabolic diseases. The company is currently developing gene therapies for diseases with high unmet needs, such as geographic atrophy, non-infectious uveitis, diabetic retinopathy, trigeminal neuralgia, epilepsy, diabetes, and glycogen storage diseases. While the company does not detail its exact approach to its development of gene therapies, it has presented several presentations on gene therapeutic-related areas, such as adeno-associated vector production by the addition of small molecules, optimizing genome titer methods, and small molecule inducible expressions of packaging genes. Kriya additionally developed integrated infrastructure for the purpose of engineering, developing, and manufacturing gene therapeutics at scale.

Novel therapies to reboot cells and organs

Cell & Gene Therapy

Kriya Therapeutics buys scientific advisor’s NASH gene therapy company

California-based Kriya Therapeutics develops gene therapies for three focus areas: ophthalmology, neurology, and metabolic diseases. The company is currently developing gene therapies for diseases with high unmet needs, such as geographic atrophy, non-infectious uveitis, diabetic retinopathy, trigeminal neuralgia, epilepsy, diabetes, and glycogen storage diseases. While the company does not detail its exact approach to its development of gene therapies, it has presented several presentations on gene therapeutic-related areas, such as adeno-associated vector production by the addition of small molecules, optimizing genome titer methods, and small molecule inducible expressions of packaging genes. Kriya additionally developed integrated infrastructure for the purpose of engineering, developing, and manufacturing gene therapeutics at scale. In November 2022, the company acquired Redpin Therapeutics, a biotechnology company developing gene therapies for intractable diseases of the nervous system, for an undisclosed amount. The acquisition was carried out to serve as the foundation for Kriya’s neurology-related gene therapy development. In January 2022, the company acquired gene therapeutic developer Warden Bio for an undisclosed sum. Through the acquisition, Kriya gained the exclusive rights to Warden Bio’s five preclinical gene therapy programs, which will serve as the foundation for Kriya’s Rare Disease division. As of May 2024, the company had nine candidates being tested across the fields of ophthalmology, metabolomics, and neurology, with three candidates being tested across each field. The company had five candidates in IND-enabling phases for the treatment of geographic atrophy, thyroid eye disease, diabetes, metabolic dysfunction-associated steatohepatitis (MASH), and trigeminal neuralgia. The company also had three candidates in discovery stages for the treatment of undisclosed diseases. Key customers and partnerships The company partnered with Twist Biopharma in March 2022 to sign an antibody discovery agreement. Through the partnership, Twist’s library of antibodies was to be combined with Kriya’s proprietary vector engineering platform to accelerate the development of novel gene therapeutics.

<div>
 
 Tenaya Therapeutics is a developer of therapeutics for heart disease. The company develops its therapeutics using precision medicine, gene therapy, and cellular regeneration. Tenaya produces therapeutics that also use proprietary in-vivo and in-vitro models. Additionally, the company has developed in-house adeno-associated virus (AAV) capsid engineering capabilities and has screened over one billion variants from more than 30 diverse, proprietary AAV libraries. The company is publicly listed on the Nasdaq and trades under the ticker symbol TNYA.&nbsp;&nbsp;
 
 
 In October 2023 Tenaya Therapeutics (Tenaya) received FDA clearance for the company&rsquo;s investigational new drug application (TN-401) to initiate clinical testing. TN-401 is Tenaya&rsquo;s adeno-associated virus serotype 9-based investigational gene therapy drug candidate for the treatment of arrhythmogenic right ventricular cardiomyopathy caused by mutations in the plakophilin-2 gene. 
 
 
 As of May 2024, the company&rsquo;s clinical pipeline included two candidates in Phase I clinical trials, a gene therapeutic for the treatment of Hypertrophic Cardiomyopathy, and a small molecule inhibitor for the treatment of heart failure with preserved ejection fraction. Additionally, Tenaya had one gene therapy candidate and two genetic medicine candidates in preclinical testing phases, along with five genetic medicine candidates in the discovery stage. 
 
 
 
</div>

Tenaya Therapeutics

<div>
 
 Sarepta Therapeutics is a gene therapy provider for conditions such as Duchenne Muscular Dystrophy (DMD), Limb-Girdle Muscular Dystrophy 
 (LGMD), and Charcot-Marie-Tooth Disease. The company&rsquo;s therapeutics incorporate technology related to gene therapy, RNA technologies, and gene editing. The company leverages a proprietary phosphorodiamidate morpholino oligomer (PMO) platform for the development of its RNA-based therapeutics. As of August 2023, the company had four FDA-approved treatments for DMD: ELEVIDYS, EXONDYS 51, VYONDYS 53, and AMONDYS 45. Sarepta Therapeutics is also listed on the Nasdaq, trading under the symbol SRPT.&nbsp;&nbsp;&nbsp;&nbsp;
 
 
 
 
 As of May 2024, the company had several RNA, gene, and gene editing therapeutics in various clinical stages. Sarepta had two RNA therapeutics, both for the treatment of DMD, one in clinical testing, and the other in pre-clinical testing. Additionally, the company had six gene therapeutics, one for the treatment of DMD (both in clinical testing), four for the treatment of LGMD (three in clinical testing, one in preclinical testing) and one for multiple targets (in preclinical testing). Also, Sarepta had two gene editing-based therapeutics in development for the treatment of DMD, both in preclinical testing phases. 
 
 
 
 
 Key customers and partnerships
 
 
 
 
 Over the years since its founding, Sarepta has partnered with several industry and academic partners. The list includes Dyno Therapeutics, Genethon, Genevant Sciences, Hansa Biopharma, Roche, Columbia University, Harvard University, Translational Laboratory of Murdoch University, University of Florida College of Medicine, The Abigail Wexner Research Institute at Nationwide Children&rsquo;s Hospital, University of Massachusetts Medical School, and the University of Western Australia.&nbsp;&nbsp;
 
 
 
 
 In October 2021, Sarepta and healthcare giant Roche announced they would collaborate on carrying out a clinical study of Sarepta&rsquo;s therapeutic candidate SRP-9001 for the treatment of DMD.&nbsp;
 
 
 
 
 Sarepta and pharmaceutical company Catalent announced that in January 2023, the companies were signing a commercial supply agreement. Through the agreement,&nbsp; Catalent would manufacture Sarepta&rsquo;s gene therapeutic for the treatment of DMD; delandistrogene moxeparvovec (SRP-9001).
 
 
 
</div>

Sarepta Therapeutics

<div>
 
 Mesoblast is a cell therapy manufacturer that provides therapeutics for oncology, cardiovascular, orthopedic, hematology, immunity, and inflammation-related conditions. The company is listed on the Australian Stock Exchange and trades under the ticker symbol &ldquo;MSB.&rdquo; Mesoblast develops therapeutics using its proprietary mesenchymal lineage cell technology platform, which is used to produce cryopreserved, off-the-shelf, and cellular-based solutions. The company also incorporates 3D bioreactor technology and automation into its production process to produce higher yields.&nbsp;
 
 
 
 
 As of May 2024, the company had five candidates that are in various stages of clinical testing. Mesoblast&rsquo;s steroid-refractory candidate for Acute Graft Versus Host Disease is currently in late-stage Phase III clinical testing and is the closest candidate to commercialization. The company&rsquo;s drug candidates for acute respiratory distress syndrome, chronic low back pain, and chronic heart failure and reduced ejection fraction are also in Phase III clinical testing while its candidate for inflammatory bowel disease is in Phase II of clinical testing.&nbsp;
 
 
 
 
 Key customers and partnerships
 
 
 
 
 The company has secured several agreements with international companies with regard to development and commercialization of Mesoblast&rsquo;s candidates, including Gr&uuml;nenthal GmBH, JCR Pharmaceuticals, Tasly Pharmaceutical Group, TiGenix NV, and the Lonza Group.&nbsp;
 
 
 
 
 Additionally, in April 2020, Mesoblast partnered with The US NIH&rsquo;s National Heart, Lung, and Blood Institute to conduct testing of its allogeneic mesenchymal stem cell (MSC) product candidate, &ldquo;remestemcel-L.&rdquo;&nbsp;&nbsp;&nbsp;&nbsp;
 
 
 
 
 
</div>

Mesoblast

<div>
 
 Ocugen is a gene therapy manufacturer that develops vaccine, cell, and gene-based therapeutics for infectious, eye, and orthopedic diseases. Its cell therapy includes a three dimensional tissue-engineered cartilage disk through the growth of chondrocytes &ndash; the cells responsible for maintaining cartilage health. Its gene therapy solution consists of creating a copy of the patient&rsquo;s gene in order to replace mutated/damaged genes. The company is publicly listed on the Nasdaq, and trades under the symbol &lsquo;OCGN&rsquo;.&nbsp;
 
 
 As of May 2024, the company had five therapeutic solutions being clinically tested. The company was developing four gene therapies for the treatment of retinitis pigmentosa, Leber congenital amaurosis, geographic atrophy, and orphan disease. Its treatment candidate for retinitis pigmentosa was in Phase III of clinical study, while its other gene therapies were in Phase I/II. 
 Ocugen was also developing a biological material, in the IND stage, for diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration. The company's cell therapy for the treatment of articular cartilage defects in the knee was in Phase III of clinical study. Finally, the company was also developing three vaccines, all in IND stages, for prevention of diseases caused by the flu, Covid-19, and a combination of the flu and Covid-19.
 
 
 Key customers and partnerships
 
 
 Ocugen partnered with biopharmaceutical manufacturer Jubilant HollisterStier of Spokane in June 2021 to manufacture its Covid-19 therapeutic COVAXIN. Through the partnership, Jubilant would be the potential commercial manufacturer of Ocugen&rsquo;s vaccine for the US and Canadian markets.
 
 
 
 
 
</div>

Ocugen

<div>
 
 MeiraGTx is a developer of gene therapies that aim to treat ocular diseases and problems, neurodegenerative disorders, and salivary gland and autoimmune disorders. MeriaGTx is also developing riboswitch-inducible expression programs for the treatment of inherited obesity and Wilson disease, along with producing small-molecule riboswitch inducers. The company is listed on the Nasdaq and trades under the symbol MGTX.&nbsp;&nbsp;
 
 
 As of May 2024, the company had four gene-based therapeutic candidates in Phase II of their clinical trials for the treatment of (1) xerostomia, Parkinson's Disease, and RPE65-Associated retinal dystrophy and (2) achromatopsia. The company also had one therapeutic being developed to treat Sjogren&rsquo;s Syndrome that was in Phase I/II of its clinical trials. Additionally, MeiraGTx had seven other therapeutics in discovery/preclinical stages. The company was also developing a therapeutic for X-linked retinitis pigmentosa in collaboration with Janssen, which was in Phase III of clinical trials. 
 
 
 Key customers and partnerships
 
 
 MeiraGTx partnered with the International Institute of Risk and Safety Management (IIRSM) in November 2022 to influence risk agendas, raise awareness, the standards of risk, and safety management across the industry.&nbsp;
 
 
 Funding and financials
 
 
 Meira last raised funds in October 2023, when the company secured a strategic investment of USD 30 million from Sanofi. As part of the transaction, Sanofi was granted the right of first negotiation for MeiraGTx's gene regulation technology in certain targets.&nbsp;
 
 
 
</div>

MeiraGTx

Companies producing cells, genes, tissues, and biomaterials such as exosomes and extracellular matrix for drug developers and pharmaceutical companies developing regenerative medicine

Chimeric antigen receptor T-cell (CAR-T) therapy involves genetically engineering T cells to target and kill cancer cells

Companies conducting R&D on therapies that modify or introduce new genes into the body to treat diseases

Includes therapies that use cells (other than CAR-T and stem cells) such as Adipose-Derived Regenerative Cells (ADRCs), cardiosphere-derived cells, and gamma delta T cells (GDT cells)

Stem cell therapy involves using stem cells usually extracted from the bone marrow and umbilical cord blood to repair a variety of diseases

Startups in the hub consider individual patient profiles, involving variability in genes, environment, and lifestyle

Genomics helps understand the genetic information stored in the DNA to develop targeted treatments

Kriya Therapeutics

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless